- Home
- LNZA vs TSHA Comparison
LNZA vs TSHA Comparison
Compare LNZA & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- TSHA
- Stock Information
- Founded
- LNZA 2005
- TSHA 2019
- Country
- LNZA United States
- TSHA United States
- Employees
- LNZA N/A
- TSHA N/A
- Industry
- LNZA Major Chemicals
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- LNZA Industrials
- TSHA Health Care
- Exchange
- LNZA Nasdaq
- TSHA Nasdaq
- Market Cap
- LNZA 340.2M
- TSHA 403.7M
- IPO Year
- LNZA N/A
- TSHA 2020
- Fundamental
- Price
- LNZA $1.02
- TSHA $1.85
- Analyst Decision
- LNZA Strong Buy
- TSHA Strong Buy
- Analyst Count
- LNZA 4
- TSHA 8
- Target Price
- LNZA $5.75
- TSHA $6.63
- AVG Volume (30 Days)
- LNZA 607.3K
- TSHA 4.9M
- Earning Date
- LNZA 11-08-2024
- TSHA 11-13-2024
- Dividend Yield
- LNZA N/A
- TSHA N/A
- EPS Growth
- LNZA N/A
- TSHA N/A
- EPS
- LNZA N/A
- TSHA N/A
- Revenue
- LNZA $58,025,000.00
- TSHA $9,915,000.00
- Revenue This Year
- LNZA N/A
- TSHA N/A
- Revenue Next Year
- LNZA $102.41
- TSHA N/A
- P/E Ratio
- LNZA N/A
- TSHA N/A
- Revenue Growth
- LNZA 7.99
- TSHA N/A
- 52 Week Low
- LNZA $0.84
- TSHA $1.19
- 52 Week High
- LNZA $5.73
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- LNZA 43.72
- TSHA 38.54
- Support Level
- LNZA $0.84
- TSHA $1.80
- Resistance Level
- LNZA $1.04
- TSHA $2.72
- Average True Range (ATR)
- LNZA 0.09
- TSHA 0.23
- MACD
- LNZA 0.02
- TSHA -0.10
- Stochastic Oscillator
- LNZA 51.43
- TSHA 3.81
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a nature-based carbon refining company that transforms waste carbon into the chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging that people use in their daily lives. The company's goal is to reduce the need for virgin fossil fuels by challenging and striving to change the way the world uses carbon.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.